Hodgkin Lymphoma
The latest news, research, and perspectives in Hodgkin lymphoma. Both types of Hodgkin lymphoma, classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma, affect the lymphatic system and advances in diagnosis and treatment have led to high cure rates.
Advertisement
Advertisement
A phase I clinical trial on IDP-023 is currently enrolling patients.
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Susan Parsons, MD, MRP; Andrew Evans, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the HoLISTIC consortium.
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
Single-cell analysis has shed new light on the unique biology of classic Hodgkin lymphoma (HL).
The primary objective of the phase II portion was to evaluate the two-year PFS rate with the treatment.
Dr. Bartlett and the hosts explore the history of first-line treatments for patients with Hodgkin lymphoma.
Key advances in understanding and detecting ctDNA could usher in a future with less invasive, but more informative biopsies.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
In this video interview, Dr. Mats Ehinger discusses the future of flow cytometry in lymphoma diagnostics.
Multiple regression did not define any independent predictor of response for early evaluation among the baseline parameters.
Most patients were able to avoid escBEACOPP plus radiotherapy based on PET results.
The study compared nivolumab plus AVD with brentuximab vedotin plus AVD in advanced stage classic Hodgkin lymphoma.
The study showed that nivolumab plus AVD improved PFS over brentuximab vedotin plus AVD.
BV-AVEPC showed “consistent efficacy” in pediatric patients across age groups “despite lower exposure."
Graham Collins, MD, discusses how to navigate the latest research in Hodgkin lymphoma.
Post-AHSCT consolidation with brentuximab vedotin plus nivolumab was “highly active” in relapsed/refractory Hodgkin ...
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
